Terms: = Bone cancer AND MTOR, FRAP2, FRAP1, 2475, ENSG00000198793, P42345, RAPT1, RAFT1, FRAP, FLJ44809
648 results:
1. IFNα-induced BST2
Zheng C; Wang J; Zhou Y; Duan Y; Zheng R; Xie Y; Wei X; Wu J; Shen H; Ye M; Kong B; Liu Y; Xu P; Zhang Q; Liang T
Cell Rep; 2024 Apr; 43(4):114088. PubMed ID: 38602878
[TBL] [Abstract] [Full Text] [Related]
2. Exosome miR-101-3p derived from bone marrow mesenchymal stem cells promotes radiotherapy sensitivity in non-small cell lung cancer by regulating DNA damage repair and autophagy levels through EZH2.
Sun H; Zhu R; Guo X; Zhao P; Zhang R; Zhao Z; Zhou H
Pathol Res Pract; 2024 Apr; 256():155271. PubMed ID: 38574630
[TBL] [Abstract] [Full Text] [Related]
3. Lapatinib antitumor effect is associated with PI3K and MAPK pathway: An analysis in human and canine prostate cancer cells.
Fonseca-Alves CE; Leis-Filho AF; Lacerda ZA; de Faria Lainetti P; Amorim RL; Rogatto SR
PLoS One; 2024; 19(4):e0297043. PubMed ID: 38564578
[TBL] [Abstract] [Full Text] [Related]
4. Morusin inhibits breast cancer-induced osteolysis by decreasing phosphatidylinositol 3-kinase (PI3K)-mtor signalling.
Zhang L; Li W; Chen X; Cao D; You S; Shi F; Luo Z; Li H; Zeng X; Song Y; Li N; Akimoto Y; Rui G; Chen Y; Wu Z; Xu R
Chem Biol Interact; 2024 May; 394():110968. PubMed ID: 38522564
[TBL] [Abstract] [Full Text] [Related]
5. c-MET pathway in human malignancies and its targeting by natural compounds for cancer therapy.
Mohan CD; Shanmugam MK; Gowda SGS; Chinnathambi A; Rangappa KS; Sethi G
Phytomedicine; 2024 Jun; 128():155379. PubMed ID: 38503157
[TBL] [Abstract] [Full Text] [Related]
6. Mefenamic acid exhibits antitumor activity against osteosarcoma by impeding cell growth and prompting apoptosis in human osteosarcoma cells and xenograft mice model.
Ye J; Chang T; Zhang X; Wei D; Wang Y
Chem Biol Interact; 2024 Apr; 393():110931. PubMed ID: 38423378
[TBL] [Abstract] [Full Text] [Related]
7. Identifying squalene epoxidase as a metabolic vulnerability in high-risk osteosarcoma using an artificial intelligence-derived prognostic index.
Wang Y; Ma X; Xu E; Huang Z; Yang C; Zhu K; Dong Y; Zhang C
Clin Transl Med; 2024 Feb; 14(2):e1586. PubMed ID: 38372422
[TBL] [Abstract] [Full Text] [Related]
8. LncRNA RPARP-AS1 promotes the progression of osteosarcoma cells through regulating lipid metabolism.
Cai F; Liu L; Bo Y; Yan W; Tao X; Peng Y; Zhang Z; Liao Q; Yi Y
BMC Cancer; 2024 Feb; 24(1):166. PubMed ID: 38308235
[TBL] [Abstract] [Full Text] [Related]
9. Targeting POLRMT by a first-in-class inhibitor IMT1 inhibits osteosarcoma cell growth in vitro and in vivo.
Kong Y; Li X; Zhang H; Fu B; Jiang HY; Yang HL; Dai J
Cell Death Dis; 2024 Jan; 15(1):57. PubMed ID: 38228583
[TBL] [Abstract] [Full Text] [Related]
10. Soy isoflavones induces mitophagy to inhibit the progression of osteosarcoma by blocking the AKT/mtor signaling pathway.
Zheng Z; Zhao X; Yuan B; Jiang S; Yan R; Dong X; Yao Q; Liang H
Mol Med; 2024 Jan; 30(1):5. PubMed ID: 38191316
[TBL] [Abstract] [Full Text] [Related]
11. Solute carrier family 35 member A2 regulates mitophagy through the PI3K/AKT/mtor axis, promoting the proliferation, migration, and invasion of osteosarcoma cells.
Luo X; Zhang J; Guo C; Jiang N; Zhang F; Jiao Q; Xu K; Yang J; Qu G; Lv XB; Zhang Z
Gene; 2024 Mar; 898():148110. PubMed ID: 38151177
[TBL] [Abstract] [Full Text] [Related]
12. Combined Immunodeficiency Caused by a Novel Nonsense Mutation in LCK.
Keller B; Kfir-Erenfeld S; Matusewicz P; Hartl F; Lev A; Lee YN; Simon AJ; Stauber T; Elpeleg O; Somech R; Stepensky P; Minguet S; Schraven B; Warnatz K
J Clin Immunol; 2023 Dec; 44(1):4. PubMed ID: 38112969
[TBL] [Abstract] [Full Text] [Related]
13. Comprehensive exploration of Biochanin A as an oncotherapeutics potential in the treatment of multivarious cancers with molecular insights.
Sohel M
Phytother Res; 2024 Feb; 38(2):489-506. PubMed ID: 37905329
[TBL] [Abstract] [Full Text] [Related]
14. Prim-O-glucosylcimifugin ameliorates aging-impaired endogenous tendon regeneration by rejuvenating senescent tendon stem/progenitor cells.
Wang Y; Jin S; Luo D; He D; Yu M; Zhu L; Li Z; Chen L; Ding C; Wu X; Wu T; Huang W; Zhao X; Xu M; Xie Z; Liu Y
Bone Res; 2023 Oct; 11(1):54. PubMed ID: 37872152
[TBL] [Abstract] [Full Text] [Related]
15. Total flavonoids of Litchi chinensis Sonn. seed inhibit prostate cancer growth in bone by regulating the bone microenvironment via inactivation of the HGFR/NF-κB signaling pathway.
Zhang W; Chen T; Yang P; Li X; Zhu D; Su Z; Yang X; Jin R; Lan T; Guo H
J Ethnopharmacol; 2024 Jan; 319(Pt 3):117327. PubMed ID: 37871755
[TBL] [Abstract] [Full Text] [Related]
16. RILP inhibits tumor progression in osteosarcoma via Grb10-mediated inhibition of the PI3K/AKT/mtor pathway.
Wei Z; Xia K; Zheng D; Gong C; Guo W
Mol Med; 2023 Oct; 29(1):133. PubMed ID: 37789274
[TBL] [Abstract] [Full Text] [Related]
17. Genetic Aspects of Conjunctival Melanoma: A Review.
Chang E; Demirci H; Demirci FY
Genes (Basel); 2023 Aug; 14(9):. PubMed ID: 37761808
[TBL] [Abstract] [Full Text] [Related]
18. Programmable DNA hydrogel provides suitable microenvironment for enhancing autophagy-based therapies in intervertebral disc degeneration treatment.
Qingxin S; Kai J; Dandan Z; Linyu J; Xiuyuan C; Yubo F; Kun W; Yingchao H; Hao C; Jie S; Zhi C; Hongxing S
J Nanobiotechnology; 2023 Sep; 21(1):350. PubMed ID: 37759249
[TBL] [Abstract] [Full Text] [Related]
19. Knockdown of PRMT1 suppresses the malignant biological behavior of osteosarcoma cells and increases cisplatin sensitivity via c-Myc-mediated BCAT1 downregulation.
Li Z; Meng D; Liu Y; Bi F; Tian K; Xu J; Sun J; Gu C; Li Y
J Biochem Mol Toxicol; 2024 Jan; 38(1):e23537. PubMed ID: 37700640
[TBL] [Abstract] [Full Text] [Related]
20. Chitosan oligosaccharide suppresses osteosarcoma malignancy by inhibiting CEMIP via the PI3K/AKT/mtor pathway.
Sim I; Choe W; Ri J; Su H; Moqbel SAA; Yan W
Med Oncol; 2023 Sep; 40(10):294. PubMed ID: 37668818
[TBL] [Abstract] [Full Text] [Related]
[Next]
